Biomea Fusion Inc. (BMEA) PT Raised to $50 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Biomea Fusion (BMEA) Presents Positive Clinical Data from Initial Cohorts of Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus
June 26, 2023 6:58 AM EDTBiomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the presentation of new clinical data from the first two cohorts of patients with T2D enrolled in the Phase II portion of its ongoing Phase I/II clinical study (COVALENT-111) of BMF-219, the companys investigational oral covalent menin inhibitor.
Beta cell loss is a critical component of the etiology and pathogenesis of... More
